CAJ | 학술논문

索拉菲尼是一种口服多激酶抑制剂。通过作用于Raf激酶直接抑制肿瘤细胞增殖，还可作用于血管内皮生长因子受体1，2，3（VEGFR-1,-2,-3），以及血小板源生长因子受体-β（PDGFR-β）、受体酪氨酸激酶、抑制肿瘤新生血管生成。索拉菲尼通过抑制肿瘤细胞增殖和抗血管生成的双重作用，从而达到抗肿瘤的目的。已被多个国家批准作为首个系统治疗肝细胞肝癌的分子靶向药物。其常见不良反应包括皮肤反应、恶心、腹泻、体质量减轻、高血压等，影响了患者的长期使用依从性，进而影响治疗效果。正确地认识和管理索拉非尼的不良反应则有助于发挥索拉非尼的治疗作用，提高临床效果。本文从索拉菲尼靶向治疗的常见不良反应、发生机制及处理方法等方面进行综述。
색랍비니시일충구복다격매억제제。통과작용우Raf격매직접억제종류세포증식，환가작용우혈관내피생장인자수체1，2，3（VEGFR-1,-2,-3），이급혈소판원생장인자수체-β（PDGFR-β）、수체락안산격매、억제종류신생혈관생성。색랍비니통과억제종류세포증식화항혈관생성적쌍중작용，종이체도항종류적목적。이피다개국가비준작위수개계통치료간세포간암적분자파향약물。기상견불량반응포괄피부반응、악심、복사、체질량감경、고혈압등，영향료환자적장기사용의종성，진이영향치료효과。정학지인식화관리색랍비니적불량반응칙유조우발휘색랍비니적치료작용，제고림상효과。본문종색랍비니파향치료적상견불량반응、발생궤제급처리방법등방면진행종술。
Sorafenib is a novel oral multikinase inhibitor that inhibits Raf kinase because of its anti-proliferative property. Sorafenib also inhibits receptor tyrosine kinases of multiple proangiogenic factors, such as VEGFR-1/2/3 and PDGFR-β. The combina-tion of both its anti-proliferative and anti-angiogenic properties makes sorafenib an attractive agent in cancer treatment. To date, sorafenib is the only approved systemic treatment for patients with hepatocellular carcinoma. The most common adverse events of this inhibitor included hand-foot skin reactions, nausea, diarrhea, weight loss, and hypertension. These adverse events can severely affect patient compliance, which may negate the effect of therapy. Correct understanding and treatment of these adverse events can improve clinical outcome. This paper discusses the clinical aspect of sorafenib-induced adverse events and the molecular basis behind their toxic-ity. Recommendations for the management of the adverse effects are also provided.